BR112023002984A2 - Formulações de anticorpo terapêutico - Google Patents

Formulações de anticorpo terapêutico

Info

Publication number
BR112023002984A2
BR112023002984A2 BR112023002984A BR112023002984A BR112023002984A2 BR 112023002984 A2 BR112023002984 A2 BR 112023002984A2 BR 112023002984 A BR112023002984 A BR 112023002984A BR 112023002984 A BR112023002984 A BR 112023002984A BR 112023002984 A2 BR112023002984 A2 BR 112023002984A2
Authority
BR
Brazil
Prior art keywords
therapeutic antibody
antibody formulations
formulations
therapeutic
stable pharmaceutical
Prior art date
Application number
BR112023002984A
Other languages
English (en)
Inventor
Paul Markham Aaron
Huaiqiu Shi Galen
Cody Thomas Justin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BR112023002984A2 publication Critical patent/BR112023002984A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

FORMULAÇÕES DE ANTICORPO TERAPÊUTICO. A presente invenção refere-se a formulações farmacêuticas estáveis para anticorpos anti-IL-23p19 terapêuticos e métodos para uso de tais referidas formulações farmacêuticas estáveis.
BR112023002984A 2020-09-10 2021-09-10 Formulações de anticorpo terapêutico BR112023002984A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063076600P 2020-09-10 2020-09-10
PCT/US2021/049773 WO2022056202A1 (en) 2020-09-10 2021-09-10 Therapeutic antibody formulations

Publications (1)

Publication Number Publication Date
BR112023002984A2 true BR112023002984A2 (pt) 2023-04-04

Family

ID=78232370

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023002984A BR112023002984A2 (pt) 2020-09-10 2021-09-10 Formulações de anticorpo terapêutico

Country Status (19)

Country Link
US (1) US20230322913A1 (pt)
EP (1) EP4210749A1 (pt)
JP (1) JP2023541249A (pt)
KR (1) KR20230066592A (pt)
CN (1) CN116437963A (pt)
AR (1) AR123477A1 (pt)
AU (1) AU2021339759A1 (pt)
BR (1) BR112023002984A2 (pt)
CA (1) CA3191114A1 (pt)
CL (1) CL2023000667A1 (pt)
CO (1) CO2023002864A2 (pt)
CR (1) CR20230122A (pt)
DO (1) DOP2023000048A (pt)
EC (1) ECSP23017107A (pt)
IL (1) IL301104A (pt)
MX (1) MX2023002889A (pt)
PE (1) PE20231191A1 (pt)
TW (1) TW202224702A (pt)
WO (1) WO2022056202A1 (pt)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1656170T (pt) 2003-08-12 2019-05-31 Lilly Co Eli Aparelho para dispensar medicação com parafusos com rosca tripla para vantagem mecânica
JP4874233B2 (ja) 2004-03-30 2012-02-15 イーライ リリー アンド カンパニー 最終用量の投与によって可能になるバネ駆動固定の特徴を持つ薬剤投与器具
ES2517420T3 (es) 2005-12-29 2014-11-03 Janssen Biotech, Inc. Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
KR101520110B1 (ko) 2007-02-23 2015-05-18 머크 샤프 앤드 돔 코포레이션 가공된 항-ＩＬ-23ｐ19 항체
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
UA110026C2 (uk) 2010-03-01 2015-11-10 Пристрій для автоматичного виконання ін'єкції з механізмом затримки, який включає в себе пересувальний елемент подвійного призначення
EP2635601B1 (en) 2010-11-04 2016-07-20 Boehringer Ingelheim International GmbH Anti-il-23 antibodies
CN104302350B (zh) 2012-03-07 2018-09-07 德卡产品有限公司 输液泵组件
TWI636063B (zh) * 2013-03-08 2018-09-21 美國禮來大藥廠 結合ｉｌ－２３之抗體
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
AR112341A1 (es) * 2017-08-02 2019-10-16 Lilly Co Eli ANTICUERPOS BIESPECÍFICOS ANTI-TNF- / ANTI-IL-23 DE IgG
WO2019246271A1 (en) * 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
TWI725532B (zh) * 2018-09-11 2021-04-21 美商美國禮來大藥廠 治療牛皮癬之方法

Also Published As

Publication number Publication date
AU2021339759A1 (en) 2023-03-16
AR123477A1 (es) 2022-12-07
ECSP23017107A (es) 2023-04-28
US20230322913A1 (en) 2023-10-12
CN116437963A (zh) 2023-07-14
WO2022056202A1 (en) 2022-03-17
MX2023002889A (es) 2023-04-18
DOP2023000048A (es) 2023-04-30
KR20230066592A (ko) 2023-05-16
CO2023002864A2 (es) 2023-03-27
PE20231191A1 (es) 2023-08-15
TW202224702A (zh) 2022-07-01
CA3191114A1 (en) 2022-03-17
CR20230122A (es) 2023-04-14
IL301104A (en) 2023-05-01
EP4210749A1 (en) 2023-07-19
JP2023541249A (ja) 2023-09-29
CL2023000667A1 (es) 2023-09-15

Similar Documents

Publication Publication Date Title
CY1123783T1 (el) Antiσωμαta enanti-b7-h3 και συζευγματα αντισωματος φαρμακου
MX2019010282A (es) Formulacion de anticuerpos monoclonales.
BR112016026811A2 (pt) formulação de anticorpo
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
PE20150891A1 (es) Anticuerpos anti-receptor de il-13 alfa 2 y conjugados de anticuerpo farmaco
BR112021019334A2 (pt) Anticorpos de cadeia pesada que se ligam ao psma
CR20190208A (es) Compuestos del péptido tirosina tirosina cíclico con anticuerpo acoplado como moduladores de receptores de neuropéptido y
BR112018075649A2 (pt) anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
CO2021010697A2 (es) Formulación de anticuerpos terapéuticos
PH12019501387A1 (en) Anti-cd3 antibody and molecules comprising the antibody
CL2020002012A1 (es) Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estas. (divisional solicitud 201903032)
BR112021016198A2 (pt) Formulações de anticorpo anti-il-36r
BR112022001575A2 (pt) Formulações de anticorpos anti-pvrig e usos dos mesmos
BR112019001233A2 (pt) formulação farmacêutica e uso da mesma
BR112021024956A2 (pt) Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
CO2021009129A2 (es) Tubulisinas y conjugados de proteína-tubulisina
BR112021004316A2 (pt) Anticorpos de agonistas anti-trem-2
CL2023001140A1 (es) Formulaciones de anticuerpos anti-pd-l1
BR112023022531A2 (pt) Conjugados de fármacos e anticorpos anti-c-met
CO2019013718A2 (es) Anticuerpos anti-trkb
AR122930A1 (es) Anticuerpos de pre-direccionamiento y métodos de uso
BR112023002984A2 (pt) Formulações de anticorpo terapêutico
BR112023024837A2 (pt) Anticorpos anti-ccr8
CO2023018650A2 (es) Formulaciones de anticuerpo anti-tgf-beta y su uso
PE20240080A1 (es) Anticuerpos anti-hbv y metodos de uso